← Back to Search

oral anti-acid treatment for Gastrocutaneous Fistula (GCF Trial)

Phase 4
Waitlist Available
Research Sponsored by University of British Columbia
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be younger than 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 1 month
Awards & highlights

GCF Trial Summary

This trial looks at whether a non-surgical bundle can help prevent or treat gastrocutaneous fistulas, which are a common complication of gastrostomy tubes.

Eligible Conditions
  • Gastrocutaneous Fistula
  • Gastrostomy Complications

GCF Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~1 month
This trial's timeline: 3 weeks for screening, Varies for treatment, and 1 month for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Gastrocutaneous Fistula (GCF)
Other outcome measures
Caregiver satisfaction Survey

GCF Trial Design

1Treatment groups
Experimental Treatment
Group I: InterventionExperimental Treatment1 Intervention
Drug administration for the experimental arm includes: AgNO3 applied to the fistula tract. A topical adhesive of either 2-Octylcyanoacrylate glue (Dermabond), or Fibrin glue, or Histoacryl glue (Tissue Seal), will be applied over the fistula's aperture. Oral anti-reflux therapy of either Pantoprazole 20-40mg PO OD, or Ranitidine 5-10mg/kg/day PO divided twice daily or 150mg PO BID, for either 4 weeks or until gastrocutaneous fistula tract closure, whichever comes first.

Find a Location

Who is running the clinical trial?

University of British ColumbiaLead Sponsor
1,413 Previous Clinical Trials
2,466,861 Total Patients Enrolled
St. Justine's HospitalOTHER
196 Previous Clinical Trials
78,929 Total Patients Enrolled
Montreal Children's Hospital of the MUHCOTHER
28 Previous Clinical Trials
114,187 Total Patients Enrolled

Media Library

oral anti-acid treatment Clinical Trial Eligibility Overview. Trial Name: NCT03920306 — Phase 4
Gastrocutaneous Fistula Research Study Groups: Intervention
Gastrocutaneous Fistula Clinical Trial 2023: oral anti-acid treatment Highlights & Side Effects. Trial Name: NCT03920306 — Phase 4
oral anti-acid treatment 2023 Treatment Timeline for Medical Study. Trial Name: NCT03920306 — Phase 4

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

How many participants are included in the current research program?

"Affirmative. Clinicaltrials.gov exhibits that this research is actively enlisting participants, since its initial posting on April 1st 2019 and latest update on January 6th 2022. 100 individuals will be welcomed across a single site for the trial's duration."

Answered by AI

What precedent exists for the effectiveness of oral anti-acid treatment, based on prior clinical trials?

"Presently, 3 studies are underway exploring oral anti-acid treatment. One of these experiments is currently in the third phase. Most research into this type of treatment is taking place in Vancouver, BC; though there are 3 other clinical sites conducting trials as well."

Answered by AI

Are there any adverse effects associated with oral anti-acid therapy?

"This oral anti-acid treatment has been given the highest safety rating of 3, due to its acceptance as an approved drug following a successful Phase 4 trial."

Answered by AI

Are new participants being accepted for this experiment at present?

"Affirmative. Clinicaltrials.gov corroborates that this study, which was initially listed on April 1st 2019, is actively recruiting volunteers. This clinical trial requires 100 candidates to be sourced from a single medical centre."

Answered by AI
~17 spots leftby Apr 2025